Emily Pimblett is SVP & Finance & CAO at Climb Bio, Inc. (CLYM). They have made 1 open-market trade across 1 company since 2024, most recently 2025-06-20.
CIK 0001969365
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLYM | SELL · 10b5-1 | 2025-06-20 | 2025-06-20 | $1.24 | $2K | +3.3% | +15.6% | +83.6% |
| CLYM | SELL · 10b5-1 | 2025-03-20 | 2025-03-20 | $1.31 | $2K | -4.0% | -1.6% | -1.6% |
| CLYM | SELL · 10b5-1 | 2024-12-19 | 2024-12-20 | $2.02 | $2K | +15.4% | -3.6% | -34.4% |
| ELYM | SELL · 10b5-1 | 2024-09-20 | 2024-09-20 | $8.18 | $10K | -40.2% | N/A | N/A |
| ELYM | SELL | 2024-06-20 | 2024-06-21 | $7.21 | $9K | -14.5% | +3.7% | +3.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.